Skip to main content
Research partnerships

Partnership funding autoimmune research now has over 10 members

Myaware, the only charity in the UK focusing on people affected by myasthenia, is the latest organisation to join Connect Immune Research.
JDRF logo placeholder for author profile picture
Kate Lawton 18 January 2023

Welcoming Myaware

Myaware, the only charity in the UK focusing on people affected by myasthenia, is the latest organisation to join Connect Immune Research. Growing the pool of experts dedicated to finding a root cause of auto immune conditions accelerates us towards innovative new ways of treating autoimmunity.

Connect Immune Research is a revolutionary partnership of organisations that research autoimmune conditions, where the body’s immune system attacks its own cells rather than viruses and bacteria. The initiative pools resources from the member organisations to fund vital research into the overlapping biology of autoimmune conditions. The more organisations we have working together, the closer we’ll be to achieving our common goal of understanding and treating the causes of autoimmunity.

Who are the current partners?

JDRF UK, Versus Arthritis, the MS Society and the British Society for Immunology founded Connect Immune Research with the mission to find shared causes of autoimmune conditions. Having recruited seven new members, the partnership now stands at 11 autoimmune research organisations, demonstrating the value the research community sees in working beyond individual conditions to tackle autoimmunity.

Dr David Coutts, Senior Research Manager at the MS Society, said: “We’re delighted to welcome myaware to our Connect Immune Research partnership. Around four million people in the UK have an autoimmune condition like multiple sclerosis, rheumatoid arthritis or type 1 diabetes, and up to a third of people live with more than one of these conditions at once. Research into autoimmune conditions often only looks at a single condition, like MS, or a single organ, like the brain. We believe by linking up research and looking for common threads, we’ll be better able to treat these conditions in the future.

“As well as speeding up research into new treatments for millions of people with autoimmune conditions, the approach could also dramatically reduce costs. We want autoimmunity to be recognised as a distinct area of research science, alongside the likes of cancer, infectious disease and dementia.”

What is myasthenia?

Myasthenia is a group of conditions, most of which are autoimmune, causing weakness in the body’s voluntary muscles and the muscles that control breathing.

Myaware, whose tagline fighting myasthenia together aligns closely with the values of Connect Immune Research, are the latest charity to join the partnership.

The wide range of organisations now united to tackle autoimmunity expands our portfolio of expertise and boosts our research prospects. Ultimately, this will help us gain crucial insights about autoimmunity that could lead to new treatments for people living with autoimmune conditions.

Related news

Read more
Hybrid closed loop technology
Type 1 technology
19 December 2023

NICE Approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales

In an historic advancement in the treatment of type 1 diabetes, the National Institute for Health and Care Excellence (NICE) today approves hybrid closed loop for the majority of people living with type 1 diabetes in England and Wales.

Read more
A woman researcher at work in a lab
Research
7 December 2023

World-first clinical trial finds drug can suppress progression of type 1 diabetes in people newly diagnosed

World-first clinical trial finds drug can suppress progression of type 1 diabetes in people newly diagnosed

Read more
Nina Willer, who used hybrid closed loop technology through pregnancy, and her child.
Treatment research
7 November 2023

Hybrid closed loop technology set to be made available in England and Wales

The announcement is the biggest treatment breakthrough for type 1 diabetes since the discovery of insulin.

Read more
T cell immune system
Research
6 November 2023

New research highlights the effectiveness of immune therapies for type 1 diabetes

The research, which was co-funded by JDRF, reveals that drugs that target the immune system offer very effective and rapid improvements in stabilising blood sugar levels, often within just three months.